A Phase 1/2 Open-Label, Single Ascending Dose Trial of a

Project: Research project

Description

A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-Associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults with Hemophilia B
StatusFinished
Effective start/end date9/17/1212/31/16

Funding

  • BAXTER HEALTHCARE CORP

Fingerprint

Hemophilia B
Dependovirus
Factor IX
Genetic Therapy
Serogroup